Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Jun 20, 2013 1:21pm

174 Views

Post# 21548927

RE: RE: RE: RE: zenith shares

But the company has recently changed "end of June" to "midyear", thus there is always a chance that next week could be a dud and we will have to wait a while longer.

Well, I don't know what was said in the recent shareholders meetings. But in the press release for completion of ASSURE enrollment (Sept 26, 2012), it indicated ASSURE results H1 2013. In the press release for completion of ASSURE dosing (April 18, 2013), it indicated ASSURE resuls mid 2013. And in the most recent blog from June 11, 2013, it indicated ASSURE results in late June. So what is your basis for saying that RVX has recently changed their estimated timeline to a later date?

Bullboard Posts

MDA Space stock blasts off on Q3 financial results